Chu-Pak Lau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Chu-Pak Lau has a total of 472 co-authors. Here are the top co-authors by number of shared publications:
- Hung-Fat Tse
Cardiology Division, Department of Medicine, Li Ka Shing Faculty of Medicine, The School of Clinical Medicine University of Hong Kong Hong Kong SAR China
31 shared publications Hung-Fat Tse
25 shared publicationsHung‐Fat Tse
Cardiology Division, Department of Medicine, School of Clinical Medicine, Queen Mary Hospital The University of Hong Kong Hong Kong SAR China
19 shared publicationsChung-Wah Siu
9 shared publications- Chung-Wah Siu
Cardiology Division, Department of Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR, China
9 shared publications Kathy Lai‐Fun Lee
Cardiology Division, Department of Medicine, School of Clinical Medicine, Queen Mary Hospital The University of Hong Kong Hong Kong SAR China
7 shared publications
Latest Publications
- 15 September 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (10) , 2427-2430
Sensor‐Driven Pacemaker Tachycardia During Chest Physiotherapy: The Hidden Accelerometer Sensor Response in a Leadless Pacemaker in the VDD Mode
Introduction: Leadless pacemakers (LPM) provide ventricular pacing, atrio‐ventricular (AV) synchrony and rate response. Background: In the VDD mode, the single‐chamber LPM is capable of atrial sensing with additional accelerometer activity sensing rate response. Methods and Results: An 85‐year‐old man with tachy‐bradycardia received a Micra AV2 (Medtronic Inc). During chest physiotherapy, pulse rate increased to over 100 bpm during chest percussion when performed on the left side. This was due to VDD mode switching to VVIR pacing when the accelerometer sensor rate exceeded the atrial rate. Inactivation of mode switching prevented rate acceleration. Conclusion: Chest physiotherapy caused unexpected rate increase in LPM even in VDD mode.
- 15 September 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (10) , 2427-2430
Sensor‐Driven Pacemaker Tachycardia During Chest Physiotherapy: The Hidden Accelerometer Sensor Response in a Leadless Pacemaker in the VDD Mode
Introduction: Leadless pacemakers (LPM) provide ventricular pacing, atrio‐ventricular (AV) synchrony and rate response. Background: In the VDD mode, the single‐chamber LPM is capable of atrial sensing with additional accelerometer activity sensing rate response. Methods and Results: An 85‐year‐old man with tachy‐bradycardia received a Micra AV2 (Medtronic Inc). During chest physiotherapy, pulse rate increased to over 100 bpm during chest percussion when performed on the left side. This was due to VDD mode switching to VVIR pacing when the accelerometer sensor rate exceeded the atrial rate. Inactivation of mode switching prevented rate acceleration. Conclusion: Chest physiotherapy caused unexpected rate increase in LPM even in VDD mode.
- Open Access
- 1 December 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (12)
Cardiac implantable electronic device upgrades and downgrades: a Clinical Consensus Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Asia Pacific Heart Rhythm Association (APHRS), Canadian Heart Rhythm Society (CHRS), Heart Rhythm Society (HRS), and the Latin American Heart Rhythm Society (LAHRS)
Cardiac implantable electronic device upgrade and downgrade procedures are increasingly being performed. Whilst the most appropriate guideline-recommended device may have been followed during a patient's initial procedure, the requirements of patients can change over time. This could be due to worsening of cardiac function due to detrimental effects of pacing itself or the diagnosis, development, or progression of another cardiac comorbidity. Device downgrades are also performed when a patient's clinical state changes and are often considered in patients with increased frailty and comorbidity. This clinical consensus statement aims to provide a framework for screening patients for device upgrade, pre-procedural planning considerations, available procedural strategies, namely a summary of techniques and approaches for vascular access, including ipsilateral and contralateral options, and a framework for when extraction to gain access may be appropriate. The document also provides advice on how to frame an ethical discussion with patients and carers on available options.
- 1 December 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (12)
Open AccessCardiac implantable electronic device upgrades and downgrades: a Clinical Consensus Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Asia Pacific Heart Rhythm Association (APHRS), Canadian Heart Rhythm Society (CHRS), Heart Rhythm Society (HRS), and the Latin American Heart Rhythm Society (LAHRS)
Cardiac implantable electronic device upgrade and downgrade procedures are increasingly being performed. Whilst the most appropriate guideline-recommended device may have been followed during a patient's initial procedure, the requirements of patients can change over time. This could be due to worsening of cardiac function due to detrimental effects of pacing itself or the diagnosis, development, or progression of another cardiac comorbidity. Device downgrades are also performed when a patient's clinical state changes and are often considered in patients with increased frailty and comorbidity. This clinical consensus statement aims to provide a framework for screening patients for device upgrade, pre-procedural planning considerations, available procedural strategies, namely a summary of techniques and approaches for vascular access, including ipsilateral and contralateral options, and a framework for when extraction to gain access may be appropriate. The document also provides advice on how to frame an ethical discussion with patients and carers on available options.
- 17 September 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (10) , 2643-2647
Adverse Effect of Ventricular Rate Regularization Pacing in Biventricular Cardiac Resynchronization Therapy
Introduction: Ventricular pacing at a shorter cycle length to premature ventricular contractions (PVCs), termed either as ventricular rate regularisation (VRR) or rate smoothing can be used to increase the percentage of biventircualr pacing and to avoid the long‐short‐long sequence caused by PVCs causing ventricular tachycardias (VTs). However, the risk of inappropriate rate increase by VRR during frequent PVCs in worsening heart failure in patients with CRT‐D has not been reported. Methods and Results: A 72‐year‐old man with dilated cardiomyopathy and atrial fibrillation received a CRT‐D after atrioventricular nodal ablation. He presented with heart failure and a persistent biventricular (BV) pacing rate of over 100 bpm. Frequent PVCs and non‐sustained VT increased and sustained the pacing rate through VRR. Rate amelioration was partially achieved with antiarrhythmic medications and normalised by inactivation of VRR. Conclusion: In patients with CRT‐D and frequent PVCs, VRR should be considered as a cause for inappropriate pacing rate that could worsen heart failure.
- 17 September 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (10) , 2643-2647
Adverse Effect of Ventricular Rate Regularization Pacing in Biventricular Cardiac Resynchronization Therapy
Introduction: Ventricular pacing at a shorter cycle length to premature ventricular contractions (PVCs), termed either as ventricular rate regularisation (VRR) or rate smoothing can be used to increase the percentage of biventircualr pacing and to avoid the long‐short‐long sequence caused by PVCs causing ventricular tachycardias (VTs). However, the risk of inappropriate rate increase by VRR during frequent PVCs in worsening heart failure in patients with CRT‐D has not been reported. Methods and Results: A 72‐year‐old man with dilated cardiomyopathy and atrial fibrillation received a CRT‐D after atrioventricular nodal ablation. He presented with heart failure and a persistent biventricular (BV) pacing rate of over 100 bpm. Frequent PVCs and non‐sustained VT increased and sustained the pacing rate through VRR. Rate amelioration was partially achieved with antiarrhythmic medications and normalised by inactivation of VRR. Conclusion: In patients with CRT‐D and frequent PVCs, VRR should be considered as a cause for inappropriate pacing rate that could worsen heart failure.
- Open Access
- 29 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 5 (5) , oeaf120
Development of three-step holistic care pathways to detect and manage comorbidities in patients with atrial fibrillation: the Horizon 2020 EHRA-PATHS consortium
Aims: Older patients with AF (≥65 years) have on average four additional comorbidities. Comorbidity management requires a systematic approach for identification, and interdisciplinary care, often lacking in clinical practice. The EHRA-PATHS project’s overall aim is to create an approach to systematically address multimorbidity in older patients with AF. Methods and results: This project involves a consortium of 14 partners from 11 European countries. The comorbidity care pathways were developed using a stepwise approach. (i) A literature study. (ii) Online meetings/discussions to create structured care pathways. (iii) A two-round Delphi study for consensus on the final pathways (agreement ≥80%) and to rank the comorbidities for priority. (iv) Selection of comorbidities for evaluation in the planned randomized controlled trial (RCT). Development of care pathways for 23 comorbidities or special clinical settings was obtained and agreed upon. The Delphi surveys were sent to 37 consortium experts. After round 1 (28 responses), 13 pathways reached an agreement ≥80%. Twelve adjusted pathways were presented in round 2 (27 responses), of which 8 received an agreement ≥80%. The last four pathways were finalized after expert consensus. Hypertension, heart failure, and overweight were ranked as the most important comorbidities. Conclusion: A structured process of expert meetings and two Delphi rounds led to the development and ranking of 23 concise care pathways to identify and manage comorbidities in patients with AF. All pathways will be combined into a software tool, providing clinicians with a systematic approach to comorbidity management, which will be tested in the RCT of EHRA-PATHS.
- 29 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 5 (5) , oeaf120
Open AccessDevelopment of three-step holistic care pathways to detect and manage comorbidities in patients with atrial fibrillation: the Horizon 2020 EHRA-PATHS consortium
Aims: Older patients with AF (≥65 years) have on average four additional comorbidities. Comorbidity management requires a systematic approach for identification, and interdisciplinary care, often lacking in clinical practice. The EHRA-PATHS project’s overall aim is to create an approach to systematically address multimorbidity in older patients with AF. Methods and results: This project involves a consortium of 14 partners from 11 European countries. The comorbidity care pathways were developed using a stepwise approach. (i) A literature study. (ii) Online meetings/discussions to create structured care pathways. (iii) A two-round Delphi study for consensus on the final pathways (agreement ≥80%) and to rank the comorbidities for priority. (iv) Selection of comorbidities for evaluation in the planned randomized controlled trial (RCT). Development of care pathways for 23 comorbidities or special clinical settings was obtained and agreed upon. The Delphi surveys were sent to 37 consortium experts. After round 1 (28 responses), 13 pathways reached an agreement ≥80%. Twelve adjusted pathways were presented in round 2 (27 responses), of which 8 received an agreement ≥80%. The last four pathways were finalized after expert consensus. Hypertension, heart failure, and overweight were ranked as the most important comorbidities. Conclusion: A structured process of expert meetings and two Delphi rounds led to the development and ranking of 23 concise care pathways to identify and manage comorbidities in patients with AF. All pathways will be combined into a software tool, providing clinicians with a systematic approach to comorbidity management, which will be tested in the RCT of EHRA-PATHS.
- Open Access
- 3 June 2025
- Published by Wiley
ADVERSE EFFECT OF VENTRICULAR RATE REGULARIZATION PACING IN BIVENTRICULAR CARDIAC RESYNCHRONIZATION THERAPY
Introduction Ventricular pacing at a shorter cycle length to premature ventricular contractions (PVCs), termed either as ventricular rate regularisation (VRR) or rate smoothing can avoid the long-short-long sequence caused by PVCs to induce ventricular tachycardias (VTs). However, the risk of inappropriate rate increase by VRR during frequent PVCs in worsening heart failure in patients with CRT-D has not been reported. Methods and results A 72-year-old man with dilated cardiomyopathy and atrial fibrillation received a CRT-D after atrioventricular nodal ablation. He presented with heart failure and a persistent biventricular (BV) pacing rate of over 100 bpm. Frequent PVCs and non-sustained VT increased and sustained the pacing rate through VRR. Rate amelioration was partially achieved with antiarrhythmic medications and normalised by inactivation of VRR. Conclusion In patients with frequent PVCs, VRR should be avoided to prevent high pacing rate and worsening heart failure even if pacing was biventricularly delivered.
- 3 June 2025
- Published by Wiley
Open AccessADVERSE EFFECT OF VENTRICULAR RATE REGULARIZATION PACING IN BIVENTRICULAR CARDIAC RESYNCHRONIZATION THERAPY
Introduction Ventricular pacing at a shorter cycle length to premature ventricular contractions (PVCs), termed either as ventricular rate regularisation (VRR) or rate smoothing can avoid the long-short-long sequence caused by PVCs to induce ventricular tachycardias (VTs). However, the risk of inappropriate rate increase by VRR during frequent PVCs in worsening heart failure in patients with CRT-D has not been reported. Methods and results A 72-year-old man with dilated cardiomyopathy and atrial fibrillation received a CRT-D after atrioventricular nodal ablation. He presented with heart failure and a persistent biventricular (BV) pacing rate of over 100 bpm. Frequent PVCs and non-sustained VT increased and sustained the pacing rate through VRR. Rate amelioration was partially achieved with antiarrhythmic medications and normalised by inactivation of VRR. Conclusion In patients with frequent PVCs, VRR should be avoided to prevent high pacing rate and worsening heart failure even if pacing was biventricularly delivered.
- 8 April 2025
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 48 (6) , 649-650
Postmortem Removal of Submuscularly Placed Subcutaneous Implantable Cardioverter Defibrillator in the Obese
- 8 April 2025
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 48 (6) , 649-650
Postmortem Removal of Submuscularly Placed Subcutaneous Implantable Cardioverter Defibrillator in the Obese
- Open Access
- 1 January 2025
- Published by Hong Kong College of Cardiology in Journal of the Hong Kong College of Cardiology
- Vol. 32 (1) , 1
The New Era of Arrhythmia Care: Innovation, Intervention & Issues
- 1 January 2025
- Published by Hong Kong College of Cardiology in Journal of the Hong Kong College of Cardiology
- Vol. 32 (1) , 1
Open AccessThe New Era of Arrhythmia Care: Innovation, Intervention & Issues
- Open Access
- 1 January 2025
- Published by Hong Kong College of Cardiology in Journal of the Hong Kong College of Cardiology
- Vol. 32 (1) , 3
Oral Anticoagulation in the Era of Continuous Rhythm Monitoring
Background Primary prevention of stroke using oral anticoagulants (OACs) is indicated for clinical atrial fibrillation (AF) documented on standard electrocardiogram (ECG) in those patients with a high risk of stroke. The recent availability of both external ECG monitors (either using consumer electronic or medical devices) and implantable devices have enabled earlier AF episodes to be detected before clinical AF become manifest. These episodes, often termed subclinical AF (SCAF), represent an area of controversy for the application of OAC. Objective The present review summarises the management of SCAF, based on recent guidelines and publications in the following areas: In the presence of an established thromboembolic (TE) event such as a stroke, diagnostic screening by either external or implantable devices are indicated. After SCAF detection, OACs will be required in the absence of contraindication for secondary prevention. In subjects at high risk for stroke, the evidence of AF screening to reduce TE events is inconclusive in several studies. This is in part due to lack of a clear follow up management pathway for managing screened detected AF patients for evaluation and treatment, such that not all high-risk subjects received OACs. The role of OACs in incidentally detected SCAF by implanted devices that utilise an atrial lead was addressed by 2 recent randomised studies, with controversial results. Conclusion SCAF provides an opportunity for AF detection before it becomes clinically manifest. The treatment paradigm is beginning to be defined by current trials.
- 1 January 2025
- Published by Hong Kong College of Cardiology in Journal of the Hong Kong College of Cardiology
- Vol. 32 (1) , 3
Open AccessOral Anticoagulation in the Era of Continuous Rhythm Monitoring
Background Primary prevention of stroke using oral anticoagulants (OACs) is indicated for clinical atrial fibrillation (AF) documented on standard electrocardiogram (ECG) in those patients with a high risk of stroke. The recent availability of both external ECG monitors (either using consumer electronic or medical devices) and implantable devices have enabled earlier AF episodes to be detected before clinical AF become manifest. These episodes, often termed subclinical AF (SCAF), represent an area of controversy for the application of OAC. Objective The present review summarises the management of SCAF, based on recent guidelines and publications in the following areas: In the presence of an established thromboembolic (TE) event such as a stroke, diagnostic screening by either external or implantable devices are indicated. After SCAF detection, OACs will be required in the absence of contraindication for secondary prevention. In subjects at high risk for stroke, the evidence of AF screening to reduce TE events is inconclusive in several studies. This is in part due to lack of a clear follow up management pathway for managing screened detected AF patients for evaluation and treatment, such that not all high-risk subjects received OACs. The role of OACs in incidentally detected SCAF by implanted devices that utilise an atrial lead was addressed by 2 recent randomised studies, with controversial results. Conclusion SCAF provides an opportunity for AF detection before it becomes clinically manifest. The treatment paradigm is beginning to be defined by current trials.